Short Interest in Dogwood Therapeutics, Inc (NASDAQ:DWTX) Drops By 40.0%

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the recipient of a large drop in short interest during the month of May. As of May 29th, there was short interest totaling 65,085 shares, a drop of 40.0% from the May 14th total of 108,418 shares. Based on an average daily volume of 44,667 shares, the days-to-cover ratio is presently 1.5 days. Approximately 0.2% of the company’s shares are sold short.

Dogwood Therapeutics Stock Down 4.5%

DWTX stock traded down $0.07 during midday trading on Tuesday, reaching $1.50. 26,638 shares of the company’s stock traded hands, compared to its average volume of 76,610. The company has a market cap of $50.45 million, a price-to-earnings ratio of -0.14 and a beta of 1.70. The firm’s fifty day moving average price is $1.68 and its 200-day moving average price is $2.99. Dogwood Therapeutics has a 52 week low of $1.28 and a 52 week high of $9.50.

Dogwood Therapeutics (NASDAQ:DWTX) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. Analysts forecast that Dogwood Therapeutics will post -0.55 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new position in Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 9.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on DWTX. Weiss Ratings lowered shares of Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, April 27th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Dogwood Therapeutics in a research note on Tuesday, May 19th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Dogwood Therapeutics currently has an average rating of “Hold” and a consensus price target of $12.00.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical?stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high?throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.